Illlumina said Tuesday that it has acquired data analysis firm Edico Genome.
Edico markets its DRAGEN platform, which uses field programmable gate array technology in combination with proprietary software algorithms to reduce data footprint and enable faster speeds. Users can run DRAGEN on site, in the cloud or in a hybrid mode, and can use a variety of different cloud storage solutions and analysis pipelines.
“Our acquisition of Edico Genome is a big step toward realizing the vision of reducing sequencing data acquisition and analysis to a push-button, standardized process,” Susan Tousi, senior vice president of product development at Illumina, said in a statement.
Edico President and CEO Pieter van Rooyen added, “As the scale of sequencing expands, decreasing the cost and time of analysis will be important to fuel the clinical adoption of sequencing.”
Stephen Kingsmore’s group at Rady Children’s Institute for Genomic Medicine has been using Edico’s DRAGEN to speed up the time-to-diagnosis for its whole-genome sequencing pipeline for critically ill infants in the NICU and has developed a rapid protocol that take just under 24 hours.
Financial details of the acquisition were not disclosed.
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).